Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.26
RHHBY's Cash to Debt is ranked lower than
91% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 42.60 vs. RHHBY: 0.26 )
Ranked among companies with meaningful Cash to Debt only.
RHHBY' s Cash to Debt Range Over the Past 10 Years
Min: 0.26  Med: 0.64 Max: N/A
Current: 0.26
Equity to Asset 0.25
RHHBY's Equity to Asset is ranked lower than
84% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RHHBY: 0.25 )
Ranked among companies with meaningful Equity to Asset only.
RHHBY' s Equity to Asset Range Over the Past 10 Years
Min: 0.09  Med: 0.25 Max: 0.59
Current: 0.25
0.09
0.59
Interest Coverage 18.16
RHHBY's Interest Coverage is ranked lower than
81% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RHHBY: 18.16 )
Ranked among companies with meaningful Interest Coverage only.
RHHBY' s Interest Coverage Range Over the Past 10 Years
Min: 5.94  Med: 10.84 Max: N/A
Current: 18.16
F-Score: 5
Z-Score: 3.62
M-Score: -2.86
WACC vs ROIC
6.41%
30.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.49
RHHBY's Operating margin (%) is ranked higher than
90% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -85.53 vs. RHHBY: 27.49 )
Ranked among companies with meaningful Operating margin (%) only.
RHHBY' s Operating margin (%) Range Over the Past 10 Years
Min: 25.03  Med: 28.74 Max: 33.69
Current: 27.49
25.03
33.69
Net-margin (%) 17.53
RHHBY's Net-margin (%) is ranked higher than
87% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -81.84 vs. RHHBY: 17.53 )
Ranked among companies with meaningful Net-margin (%) only.
RHHBY' s Net-margin (%) Range Over the Past 10 Years
Min: 15.87  Med: 18.73 Max: 22.97
Current: 17.53
15.87
22.97
ROE (%) 48.21
RHHBY's ROE (%) is ranked higher than
98% of the 858 Companies
in the Global Biotechnology industry.

( Industry Median: -31.92 vs. RHHBY: 48.21 )
Ranked among companies with meaningful ROE (%) only.
RHHBY' s ROE (%) Range Over the Past 10 Years
Min: 19.94  Med: 45.85 Max: 102.95
Current: 48.21
19.94
102.95
ROA (%) 12.44
RHHBY's ROA (%) is ranked higher than
92% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -27.48 vs. RHHBY: 12.44 )
Ranked among companies with meaningful ROA (%) only.
RHHBY' s ROA (%) Range Over the Past 10 Years
Min: 10.33  Med: 12.78 Max: 17.58
Current: 12.44
10.33
17.58
ROC (Joel Greenblatt) (%) 62.92
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 912 Companies
in the Global Biotechnology industry.

( Industry Median: -387.57 vs. RHHBY: 62.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RHHBY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 52.39  Med: 64.13 Max: 84.52
Current: 62.92
52.39
84.52
Revenue Growth (3Y)(%) 3.20
RHHBY's Revenue Growth (3Y)(%) is ranked lower than
51% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.70 vs. RHHBY: 3.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RHHBY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.5  Med: 5 Max: 394
Current: 3.2
-3.5
394
EBITDA Growth (3Y)(%) -0.40
RHHBY's EBITDA Growth (3Y)(%) is ranked lower than
51% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. RHHBY: -0.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RHHBY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.5  Med: 10.9 Max: 271.3
Current: -0.4
-2.5
271.3
EPS Growth (3Y)(%) -2.30
RHHBY's EPS Growth (3Y)(%) is ranked higher than
52% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. RHHBY: -2.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RHHBY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -3.2  Med: 6.9 Max: 340.9
Current: -2.3
-3.2
340.9
» RHHBY's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-10-22)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

RHHBY Guru Trades in Q3 2015

Ken Fisher 14,538,602 sh (+2.30%)
Mairs and Power 2,712,985 sh (+0.02%)
» More
Q4 2015

RHHBY Guru Trades in Q4 2015

Ken Fisher 14,630,453 sh (+0.63%)
Mairs and Power 2,714,500 sh (+0.06%)
» More
Q1 2016

RHHBY Guru Trades in Q1 2016

Ken Fisher 14,906,191 sh (+1.88%)
Mairs and Power 2,723,637 sh (+0.34%)
» More
Q2 2016

RHHBY Guru Trades in Q2 2016

Mairs and Power 4,005,602 sh (+47.07%)
Ken Fisher 15,142,209 sh (+1.58%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AMGN, NYSE:NVO, NAS:GILD, NAS:CELG, NAS:BIIB, NAS:SHPG, NAS:REGN, OTCPK:CSLLY, OTCPK:NVZMY, NAS:ALXN, NAS:VRTX, OTCPK:ALIOY, NAS:BMRN, OTCPK:UCBJF, NAS:INCY, NAS:MDVN, NAS:GRFS, OTCPK:GMXAY, NAS:JAZZ, NAS:ALKS » details
Traded in other countries:RHO5.Germany, ROG N.Mexico, RO.Switzerland, 0QOK.UK,
Roche Holding AG is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience.

Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology and neuroscience. It has more than 66 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals and Chugai, whereas Genentech as the former third segment has been integrated into Roche Pharmaceuticals. The Diagnostics Division consists of the following four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.

Top Ranked Articles about Roche Holding AG

Innovative Diagnostic and Therapeutic Products Seen at Roche Roche is arguably the strongest company in the biotech field​
In the world of biotechnology and pharmaceuticals, arguably the largest in the field is the company known as Roche (RHHBY). Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver great benefits to patients and healthcare professionals, from early detection and prevention of disease to treatment and treatment monitoring. Read more...
Does Biotech’s Recent Bounce Have Legs? Examining 3 Big Pharma stocks that dominate the making of cancer-fighting treatments
The beleaguered biotechology sector, which has endured political controversy amid charges of price gouging, is now on an upward trajectory. The Nasdaq Biotechnology Index, after falling 17.46% year to date, has jumped 9.04% over the past month. Read more...
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Largest trades in second quarter include also Infosys and Alibaba
Ken Fisher (Trades, Portfolio) is the chief executive officer and chief investment officer of Fisher Investments, which offers an array of educational resources to its 27,000-plus private clients —including quarterly reports, in-person seminars and regular phone communication. Fisher Investments extends these educational resources to the public through a series of investing guides, online videos and daily commentary at MarketMinder.com. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 23.01
RHHBY's P/E(ttm) is ranked higher than
59% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 28.85 vs. RHHBY: 23.01 )
Ranked among companies with meaningful P/E(ttm) only.
RHHBY' s P/E(ttm) Range Over the Past 10 Years
Min: 13.05  Med: 19.83 Max: 36.39
Current: 23.01
13.05
36.39
Forward P/E 15.77
RHHBY's Forward P/E is ranked higher than
68% of the 60 Companies
in the Global Biotechnology industry.

( Industry Median: 20.62 vs. RHHBY: 15.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 23.01
RHHBY's PE(NRI) is ranked higher than
60% of the 233 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. RHHBY: 23.01 )
Ranked among companies with meaningful PE(NRI) only.
RHHBY' s PE(NRI) Range Over the Past 10 Years
Min: 13.05  Med: 19.83 Max: 36.39
Current: 23.01
13.05
36.39
Price/Owner Earnings (ttm) 16.66
RHHBY's Price/Owner Earnings (ttm) is ranked higher than
71% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 30.57 vs. RHHBY: 16.66 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
RHHBY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.58  Med: 15.39 Max: 32.39
Current: 16.66
9.58
32.39
P/B 11.20
RHHBY's P/B is ranked lower than
84% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: 3.67 vs. RHHBY: 11.20 )
Ranked among companies with meaningful P/B only.
RHHBY' s P/B Range Over the Past 10 Years
Min: 2.64  Med: 11.26 Max: 22.21
Current: 11.2
2.64
22.21
P/S 4.14
RHHBY's P/S is ranked higher than
75% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.30 vs. RHHBY: 4.14 )
Ranked among companies with meaningful P/S only.
RHHBY' s P/S Range Over the Past 10 Years
Min: 2.38  Med: 4.13 Max: 6.05
Current: 4.14
2.38
6.05
PFCF 18.78
RHHBY's PFCF is ranked higher than
66% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 26.42 vs. RHHBY: 18.78 )
Ranked among companies with meaningful PFCF only.
RHHBY' s PFCF Range Over the Past 10 Years
Min: 8.6  Med: 17.35 Max: 36.73
Current: 18.78
8.6
36.73
POCF 13.70
RHHBY's POCF is ranked higher than
69% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. RHHBY: 13.70 )
Ranked among companies with meaningful POCF only.
RHHBY' s POCF Range Over the Past 10 Years
Min: 6.98  Med: 13.76 Max: 21.96
Current: 13.7
6.98
21.96
EV-to-EBIT 17.71
RHHBY's EV-to-EBIT is ranked higher than
59% of the 238 Companies
in the Global Biotechnology industry.

( Industry Median: 23.94 vs. RHHBY: 17.71 )
Ranked among companies with meaningful EV-to-EBIT only.
RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.6  Med: 14.1 Max: 20.7
Current: 17.71
7.6
20.7
EV-to-EBITDA 13.79
RHHBY's EV-to-EBITDA is ranked higher than
63% of the 259 Companies
in the Global Biotechnology industry.

( Industry Median: 19.79 vs. RHHBY: 13.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
RHHBY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 11.9 Max: 16.9
Current: 13.79
6.4
16.9
PEG 19.67
RHHBY's PEG is ranked lower than
98% of the 92 Companies
in the Global Biotechnology industry.

( Industry Median: 2.29 vs. RHHBY: 19.67 )
Ranked among companies with meaningful PEG only.
RHHBY' s PEG Range Over the Past 10 Years
Min: 0.24  Med: 1.18 Max: 23.21
Current: 19.67
0.24
23.21
Shiller P/E 21.61
RHHBY's Shiller P/E is ranked higher than
78% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 48.47 vs. RHHBY: 21.61 )
Ranked among companies with meaningful Shiller P/E only.
RHHBY' s Shiller P/E Range Over the Past 10 Years
Min: 18.42  Med: 23.68 Max: 34.56
Current: 21.61
18.42
34.56
Current Ratio 1.09
RHHBY's Current Ratio is ranked lower than
86% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.25 vs. RHHBY: 1.09 )
Ranked among companies with meaningful Current Ratio only.
RHHBY' s Current Ratio Range Over the Past 10 Years
Min: 1.09  Med: 1.85 Max: 3.75
Current: 1.09
1.09
3.75
Quick Ratio 0.75
RHHBY's Quick Ratio is ranked lower than
87% of the 918 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. RHHBY: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
RHHBY' s Quick Ratio Range Over the Past 10 Years
Min: 0.75  Med: 1.5 Max: 3.22
Current: 0.75
0.75
3.22
Days Inventory 179.02
RHHBY's Days Inventory is ranked lower than
65% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 132.42 vs. RHHBY: 179.02 )
Ranked among companies with meaningful Days Inventory only.
RHHBY' s Days Inventory Range Over the Past 10 Years
Min: 143.33  Med: 159.24 Max: 186.16
Current: 179.02
143.33
186.16
Days Sales Outstanding 64.10
RHHBY's Days Sales Outstanding is ranked lower than
52% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. RHHBY: 64.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
RHHBY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.32  Med: 74.15 Max: 84.09
Current: 64.1
60.32
84.09
Days Payable 57.68
RHHBY's Days Payable is ranked higher than
53% of the 422 Companies
in the Global Biotechnology industry.

( Industry Median: 53.36 vs. RHHBY: 57.68 )
Ranked among companies with meaningful Days Payable only.
RHHBY' s Days Payable Range Over the Past 10 Years
Min: 49.43  Med: 60.53 Max: 78.64
Current: 57.68
49.43
78.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.28
RHHBY's Dividend Yield is ranked higher than
87% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. RHHBY: 3.28 )
Ranked among companies with meaningful Dividend Yield only.
RHHBY' s Dividend Yield Range Over the Past 10 Years
Min: 0.99  Med: 2.88 Max: 4.55
Current: 3.28
0.99
4.55
Dividend Payout 0.77
RHHBY's Dividend Payout is ranked lower than
88% of the 120 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. RHHBY: 0.77 )
Ranked among companies with meaningful Dividend Payout only.
RHHBY' s Dividend Payout Range Over the Past 10 Years
Min: 0.61  Med: 1.09 Max: 1.38
Current: 0.77
0.61
1.38
Dividend Growth (3y) 5.60
RHHBY's Dividend Growth (3y) is ranked lower than
53% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. RHHBY: 5.60 )
Ranked among companies with meaningful Dividend Growth (3y) only.
RHHBY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 10.8 Max: 27.3
Current: 5.6
0
27.3
Forward Dividend Yield 3.29
RHHBY's Forward Dividend Yield is ranked higher than
87% of the 206 Companies
in the Global Biotechnology industry.

( Industry Median: 1.20 vs. RHHBY: 3.29 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 4.37
RHHBY's Yield on cost (5-Year) is ranked higher than
84% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 1.53 vs. RHHBY: 4.37 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
RHHBY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.32  Med: 3.84 Max: 6.06
Current: 4.37
1.32
6.06
3-Year Average Share Buyback Ratio 0.40
RHHBY's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.50 vs. RHHBY: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RHHBY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 78.5
Current: 0.4
0
78.5

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.61
RHHBY's Price/Projected FCF is ranked lower than
99.99% of the 168 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. RHHBY: 1.61 )
Ranked among companies with meaningful Price/Projected FCF only.
RHHBY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0  Med: 1.73 Max: 6.63
Current: 1.61
0
6.63
Price/DCF (Earnings Based) 2.15
RHHBY's Price/DCF (Earnings Based) is ranked lower than
89% of the 19 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. RHHBY: 2.15 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.01
RHHBY's Price/Median PS Value is ranked lower than
99.99% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. RHHBY: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
RHHBY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0  Med: 1.05 Max: 1.29
Current: 1.01
0
1.29
Earnings Yield (Greenblatt) (%) 5.70
RHHBY's Earnings Yield (Greenblatt) (%) is ranked higher than
90% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.90 vs. RHHBY: 5.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RHHBY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 4.8  Med: 7.1 Max: 13.1
Current: 5.7
4.8
13.1
Forward Rate of Return (Yacktman) (%) 6.87
RHHBY's Forward Rate of Return (Yacktman) (%) is ranked lower than
65% of the 117 Companies
in the Global Biotechnology industry.

( Industry Median: 16.42 vs. RHHBY: 6.87 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
RHHBY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 4.3  Med: 10.25 Max: 62.9
Current: 6.87
4.3
62.9

More Statistics

Revenue (TTM) (Mil) $52,759
EPS (TTM) $ 1.35
Beta0.60
Short Percentage of Float0.00%
52-Week Range $29.89 - 35.13
Shares Outstanding (Mil)6,817.65

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 53,998 58,242 65,938
EPS ($) 1.98 2.16 2.51
EPS w/o NRI ($) 1.98 2.16 2.51
EPS Growth Rate
(3Y to 5Y Estimate)
8.93%
Dividends Per Share ($) 1.07 1.14 1.21
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Can Novartis Tide Over the Alcon Crisis? Aug 26 2016 
Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
Roche Holdings Definitely Not a Lumbering Giant Jul 11 2016 
Invesco Adds to Holdings in Investment, Financial Services Companies Jul 01 2016 
Bearish Sentiment in Becton Dickinson's Stock Apr 27 2016 
Does Biotech’s Recent Bounce Have Legs? Apr 22 2016 
Invesco European Growth Fund Adds to More Than 40 Existing Stakes Apr 04 2016 
Invesco European Growth Fund Adds to 7 Stakes Jan 26 2016 
Ken Fisher Cuts His Stake in Royal Bank, Buys Roche Holding Oct 12 2015 

More From Other Websites
2:45 am Roche Hldg's Zika PCR test receives Emergency Use Authorization from the FDA Aug 30 2016
Roche (RHHBY) Stock Higher, FDA Gives Emergency Approval for Zika Test Aug 29 2016
Roche Gets FDA Nod for Emergency Use of Zika Virus Test Aug 29 2016
US Food and Drug Administration Approves Zika Test Aug 29 2016
Yestar International Holdings Company Limited -- Moody's assigns first-time Ba3 rating to Yestar;... Aug 29 2016
FDA grants Roche Zika test emergency authorization Aug 29 2016
Roche receives FDA Emergency Use Authorization for Zika PCR test Aug 29 2016
New Zika Screening Rule Could Boost Hologic Sales Growth Aug 26 2016
Why Roche Might Be Interested in BioMarin Aug 25 2016
Medivation: The Latest Analyst Recommendations Aug 24 2016
Roche Launches Accu-Chek Blood Glucose Monitoring System Aug 23 2016
Innovative Diagnostic and Therapeutic Products Seen at Roche Aug 22 2016
ROCHE HOLDING LTD /FI Financials Aug 16 2016
Movers and Shakers in Biotech: Global Blood Therapeutics Inc (GBT) and Eleven Biotherapeutics Inc... Aug 15 2016
How Did Valeant’s Segments Perform in 2Q16? Aug 12 2016
Biogen Stock Pops As Merck, Allergan Reportedly Probing Buyout Aug 02 2016
Roche launches new target enrichment systems for genetic and translational research Aug 02 2016
Roche introduces virtual reality theater at AACC 2016 Clinical Lab Expo to give lab professionals... Aug 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)